Spectral Diagnostics plans for European panel launch
This article was originally published in Clinica
Spectral Diagnostics (Canada) hopes to launch its point-of-care cardiac panel tests in Europe this year. The company is at the planning and negotiation stage, according to Dr Paul Kerth, vice-president of European operations and former scientific director of Boehringer Mannheim's troponin T development group. Dr Kerth would not name European partners but said: "Spectral is looking for a matched mind-set, not consolidation. We want a pan-European deal because despite the cultural differences, there is more and more electronic integration in clinical practice."
You may also be interested in...
Novartis’s cancer drug has now been filed for multiple sclerosis in the US, armed with a priority review, and in Europe.
Aetion is also working with the US Food and Drug Administration and a number of biopharma companies on projects involving use of real-world evidence.
Increased fines and penalties are on the cards for manufacturing facilities that fail to comply with proposed new requirements.